Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v12-EN Version v7-FR
Language English French
Date Updated 2022-12-08 2022-10-17
Drug Identification Number 02392925 02392925
Brand name TEVA-NABILONE TEVA-NABILONE
Common or Proper name TEVA-NABILONE TEVA-NABILONE
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients NABILONE NABILONE
Strength(s) 0.25MG 0.25MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL ORAL ORAL
Packaging size 50 50
ATC code A04AD A04AD
ATC description ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-09-22 2022-09-22
Estimated end date 2023-01-20 2022-12-10
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments